Nefazodone, Urine
Nefazodone is a member of the class of drugs known as antidepressants. The use of tricyclic antidepressants (TCAs) is one of the primary ways to treat clinical depression. Depression and schizophrenia are the most common mental disorders that faces mankind at this time. Other clinical uses of antidepressants are for disorders or clinical conditions such as obsessive-compulsive disorders, chronic pain, eating disorders, anxiety or panic disorders, peptic ulcer disease or childhood enuresis. Nefazodone is a member of the third generation of antidepressants.
All TCAs are well absorbed and reach peak serum concentrations within 2-12 hours. TCAs are lipophilic and have large volumes of distributions. Most TCAs are metabolized by the cytochrome P450 system and many of the metabolites are biologically active. Nefazodone is metabolized to M-chloro-phenylpiperazine hydroxynefazodone, which is also biologically active. The half-lives of these particular drugs are quite variable. The half-life of nefazodone is between 2-5 hours. Many of the therapeutic ranges for these drugs have not been established or there is non-consensus.
The effects associated with nefazodone abuse include headache, dry mouth, sexual dysfunction, hallucinations, tachycardia, seizures, nausea, vomiting, tremors, and coma when taken to excess.
Nefazodone is one of the most frequently encountered drugs of abuse due to the large majority of the population that is taking them, the frequency with which these drugs are prescribed, and their high potential for serious side effects.
- Therapeutic monitoring
- Drug abuse evaluation
- Toxicity assessment
- Patient Compliance
Therapeutic levels: 0.30-0.50 mg/L
Toxic levels: variable
Fatality levels: variable
Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration is preferred for pharmacokinetic analyses.
Cut-Off Ranges
Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection. whether it is a qualitative method such as TLC or IA, or a quantitative method such as LC/MS or GC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.
Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.
Stability
- Ambient: 3-5 days
- Refrigeration: 5-7 days
- Frozen: 30 days
- Antidepressant DEA Drug Fact Sheet.
- Levine, Barry (Ed). Therapeutic Drugs II: Antidepressants. In: Principles of Forensic Toxicology, 4th Ed. Washington DC: AACC Press; 2013: 403-420.
- Balant-Georgia AE, Balant LP. Milestones in clinical pharmacology. Therapeutic drug monitoring of antidepressants. Clin Ther. 1992;14(4):612-4.
- Baselt RC (ed). Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Littleton, MA: PSG Publishing Co.; 1987.
- Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA: Biomedical Publications; 2002.
- Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7):169-79.
- Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds). Goodman and Gilman’s the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill Co.; 1996
- Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology. 1989;11(4):7-20.
- Zherdev VP, Caccia S, Garattini S, Ekonomov AL. Species differences in phenazepam kinetics and metabolism. Euro J Drug Metab Pharm. 1982;7:191-6.